Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Free Report) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $5.12 and traded as low as $3.12. Titan Pharmaceuticals shares last traded at $3.61, with a volume of 47,798 shares changing hands.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on Titan Pharmaceuticals in a report on Friday. They issued a “sell” rating on the stock.
Get Our Latest Stock Analysis on TTNP
Titan Pharmaceuticals Trading Down 2.5 %
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- What is a Death Cross in Stocks?
- Top 3 ETFs to Hedge Against Inflation in 2025
- What Are Treasury Bonds?
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
